AXL and chronic myelogenous leukemia, BCR-ABL1 positive: Other studies also showed that the AXL inhibitors could significantly inhibit tumor growth and improve survival in animal models of different tumors including chronic myeloid leukemia, non-small cell lung cancer and acute myeloid leukemia [10], [28], [29].